Yes, Orbis. Not sure if its a good or bad thing. Probably good.
Pretty clear instructions they gave - get me 1%. Thats what happened. 1.5M elevated them to 12.2%.
I am quietly confident as these prices. QRX isnt a one-trick pony, as there are other formulations in its product suite. In my mind I consistently refer to historical developments:
1. Top-tier partners, with attractive commercial terms (others recognise value and want IN)
2. Management experience and FDA engagement
3. Product suite (one fails, whats the fall-back)
4. Insto support
5. And this:
Add to My Watchlist
What is My Watchlist?